The company had posted a net profit of Rs 5.98 crore for the corresponding period of the previous fiscal, Hester Biosciences said in a BSE filing. "The operations indicate that the large animal vaccine business has a good potential for improving the profitability of the company. The growth anticipated is also from the large animal vaccines," the company said.
PTI
@moneycontrolcom
Animal healthcare firm Hester Biosciences today reported a 47.99 per cent rise in its standalone net profit to Rs 8.85 crore for the September quarter, mainly on account of robust sales in large divisions.
The company had posted a net profit of Rs 5.98 crore for the corresponding period of the previous fiscal, Hester Biosciences said in a BSE filing. "The operations indicate that the large animal vaccine business has a good potential for improving the profitability of the company. The growth anticipated is also from the large animal vaccines," the company said.
Standalone net sales of the company also rose to Rs 38.47 crore for the quarter under consideration as against Rs 30.17 crore in the same period year ago. In a separate filing, Hester Biosciences Ltd said its board has declared an interim dividend of Rs 4 per equity share on the face value of Rs 10 per share, for the financial year 2017-18. Shares of Hester Biosciences were trading 4.80 per cent higher at Rs 1,188.60 per scrip at 1400 hrs on BSE today.
